Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Posted inDiabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.
Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antipsychotics.
Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence
Posted inClinical Updates Internal Medicine news Psychiatry

Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence

This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support technologies and peer-led interventions.
Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS
Posted inDiabetes & Endocrinology news

Tirzepatide Produces Large Real‑World Weight Loss in Women with PCOS

A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promising but require randomized, biomarker‑driven studies to define metabolic and reproductive benefits and safety in this population.
Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss
Posted inClinical Updates Diabetes & Endocrinology Family Medicine & Nutrition news Specialties

Optimizing Metabolic and Physical Health in Obese Older Adults: Impact of Exercise Modalities on Insulin Secretion, CNTF, and IGF-1 During Weight Loss

Combining aerobic and resistance exercise with diet-induced weight loss in obese older adults significantly improves insulin secretion, preserves CNTFRα levels, and increases IGF-1, enhancing metabolic and physical function.